Hoth Therapeutics Says Early Data Show HT-KIT Drug Stabilizes Tumor Growth; Shares Jump

MT Newswires Live10-30

Hoth Therapeutics (HOTH) shares advanced nearly 24% in recent Tuesday trading after the company said preliminary results of a preclinical study suggested that its HT-KIT drug inhibits and stabilizes tumor growth.

The study was undertaken through a sponsored scientific research agreement with NC State University, the company said.

Hoth said initial findings showed minimal changes in tumor volumes in treated animals, suggesting that the drug inhibited tumor growth. Tumor sizes were also consistent across the treated animals, indicating the drug's potential reproducibility and reliability, the company added.

Price: 1.09, Change: +0.21, Percent Change: +23.86

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479378382?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 01:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479378382","market":"us","top_or_hot":-1,"title":"Hoth Therapeutics Says Early Data Show HT-KIT Drug Stabilizes Tumor Growth; Shares Jump","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> (HOTH) shares advanced nearly 24% in recent Tuesday trading after the company said preliminary results of a preclinical study suggested that its HT-KIT drug inhibits and stabilizes tumor growth.</p><p>The study was undertaken through a sponsored scientific research agreement with NC State University, the company said.</p><p>Hoth said initial findings showed minimal changes in tumor volumes in treated animals, suggesting that the drug inhibited tumor growth. Tumor sizes were also consistent across the treated animals, indicating the drug's potential reproducibility and reliability, the company added.</p><p>Price: 1.09, Change: +0.21, Percent Change: +23.86</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics Says Early Data Show HT-KIT Drug Stabilizes Tumor Growth; Shares Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics Says Early Data Show HT-KIT Drug Stabilizes Tumor Growth; Shares Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 01:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hoth Therapeutics (HOTH) shares advanced nearly 24% in recent Tuesday trading after the company said preliminary results of a preclinical study suggested that its HT-KIT drug inhibits and stabilizes ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01611","symbol_name":"新火科技控股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479378382","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479378382","pubTimestamp":1730224191,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hoth Therapeutics  shares advanced nearly 24% in recent Tuesday trading after the company said preliminary results of a preclinical study suggested that its HT-KIT drug inhibits and stabilizes tumor growth.The study was undertaken through a sponsored scientific research agreement with NC State University, the company said.Hoth said initial findings showed minimal changes in tumor volumes in treated animals, suggesting that the drug inhibited tumor growth. Tumor sizes were also consistent across the treated animals, indicating the drug's potential reproducibility and reliability, the company added.Price: 1.09, Change: +0.21, Percent Change: +23.86","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01611":"新火科技控股","BK4218":"酒店及度假村房地产信托","HOTH":"Hoth Therapeutics","HT":"HT基金","A7RU.SI":"吉宝基础设施信托","BK4181":"酒店及度假村房地产投资信托","BK4007":"制药"},"translate_title":"Hoth Therapeutics表示，早期数据显示HT-KIT药物可稳定肿瘤生长；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01611":1,"A7RU.SI":1,"HOTH":1,"HT":1},"content_text":"Hoth Therapeutics (HOTH) shares advanced nearly 24% in recent Tuesday trading after the company said preliminary results of a preclinical study suggested that its HT-KIT drug inhibits and stabilizes tumor growth.The study was undertaken through a sponsored scientific research agreement with NC State University, the company said.Hoth said initial findings showed minimal changes in tumor volumes in treated animals, suggesting that the drug inhibited tumor growth. Tumor sizes were also consistent across the treated animals, indicating the drug's potential reproducibility and reliability, the company added.Price: 1.09, Change: +0.21, Percent Change: +23.86","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479378382"}